Search

Issue
Title
Authors
Evaluation of long-term results of treatment of patients with residual tumors (including those with minimal forms of ypT1abN0), with pathomorphological complete response (pCR) after neoadjuvant systemic therapy, with primary minimal breast cancer (pT1abN0M0)
Pesotsky R.S., Semiglazov V.F., Krivorotko P.V., Tabagua T.T., Zernov K.Y., Emelyanov A.S., Semiglazova T.Y., Amirov N., Mortada V.V., Ulrikh D.G., Levchenko V.E., Rychagov K.Y., Zirov K.Y., Evseev V.N.
The role of cyclin-dependent kinase inhibitors in adjuvant therapy of breast cancer
Semiglazov V.F., Krivorotko P.V., Bekkeldiyeva N.B., Komyakhov A.V., Emelyanov A.S., Gorina A.O.
Reconstructive plastic surgery of the breast using autogenous tissue. Historical aspects
Khakimova S.G., Zikiryakhodzhaev A.D., Kaprin A.D., Khakimova G.G., Onofriychuk I.M., Rasskazova E.A., Sukhotko A.S., Vlasova M.Y., Bosieva A.R., Tokaev V.K.
Primary resistance to anti-HER2 therapy: mechanisms of development and ways to overcome
Dashyan G.A., Dzhelialov E.S., Konstantinova V.V., Gronskaya Y.A., Murskikh A.D., Akhmedov R.M., Tyusenko A.E., Olchonova A.A., Dyakonenko Z.V., Sereda O.A., Belousov A.M.
Possibilities of overcoming hormone resistance in patients with metastatic HR+ HER2- breast cancer using the drug alpelisib in various subgroups in real clinical practice
Orlova R.V., Gluzman M.I., Vakhitova A.A.
GSTT1 and GSTM1 deletion polymorphism as a predictor of response to hormonal therapy for breast cancer
Gulian I.S., Bystritskaya E.P., Otstavnykh N.Y., Khudchenko E.V., Eliseeva E.V., Apanasevich V.I., Isaeva M.P.
Trastuzumab deruxtecan in the treatment of breast cancer
Semiglazov V.F., Krivorotko P.V., Bekkeldieva N.B., Gorina A.O., Komyakhov A.V., Paltuev R.M., Tabagua T.T., Ereshenko S.S.
Delay of initiation of adjuvant chemotherapy in patients with early breast cancer: causes and consequences
Dashyan G.A., Konstantinova V.V., Dzhelialov E.S., Akhmedov R.M., Semiletova Y.V., Zhurov A.S., Tyusenko A.E., Olchonova A.A., Pavlikova I.A., Belousov A.M.
The role of alpelisib in the treatment of PIK3CA - a mutated breast cancer
Semiglazov V.F., Krivorotko P.V., Komyakhov A.V., Semiglazova T.Y., Gigolaeva L.P., Tabagua T.T., Kazantseva M.D., Tergoeva A.P., Ulrikh D.G., Chervyak M.V., Klimenko V.V., Amirov N.S., Zhiltsova E.K., Semiglazov V.V.
Experience of the use of ixabepilone in polychemotherapy regimens for disseminated triple-negative breast cancer
Glazkova E.V., Frolova M.A., Menshikov S.F., Stenina M.B.
Klinicheskiy sluchay uspeshnogo lecheniya erilibulinom metastaticheskogo raka molochnoy zhelezy
Limareva S.V., Laytsan K.Y., Stroyakovskiy D.L., Demidova I.A., Gorbunova V.A.
Abemacyclib is a unique representative of the class of CDK4/6 inhibitors in the treatment of HR+/HER2- metastatic breast cancer
Grechukhina K.S., Vorontsova K.A., Kuko T.M., Prosvirnov A.A., Ganshina I.P., Lubennikova E.V., Kolyadina I.V., Zhukova L.G.
Eribulin – novyy mikrotrubochkovyy ingibitor dlya lecheniya metastaticheskogo raka molochnoy zhelezy
Stenina M.B.
LEChENIE TRIZhDY NEGATIVNOGO RAKA MOLOChNOY ZhELEZY
Semiglazov V.F., Dashyan G.A., Semiglazov V.V., Paltuev R.M., Migmanova N.S., Ivanova O.A., Tabagua T.T.
Novye vozmozhnosti ispol'zovaniya targetnoy terapii v lechenii nekotorykh solidnykh opukholey (po materialam ESMO-2014)
Dobrova N.V.
Osobennosti klinicheskogo techeniya invazivnogo dol'kovogo raka molochnoy zhelezy
Borisova E.I., Vyshinskaya G.V., Gutorov S.L., Stepanchenko M.V.
Non-small lung cancer. Expanding therapeutic opportunities: pembrolizumab in a number of malignant tumors
Gutorov S.L., Borisova E.I., Abramov M.E., Lud A.N., Arutyunyan E.A.
Perspektivy primeneniya kapsul vinorelbina v sovremennoy onkologii
Gutorov S.L., Stepanchenko M.V., Lichinitser M.R.
Neoadjuvant and postneoadjuvant treatment for triple negative breast cancer
Semiglazov V.F., Dzhelyalova M.A., Tseluyko A.I., Pesotsky R.S., Bessonov A.A., Semiglazova T.Y.
EVEROLIMUS (AFINITOR): NOVYE VOZMOZhNOSTI TERAPII ZLOKAChESTVENNYKh OPUKhOLEY
Gorbunova V.A.
Sentinel lymph node scintigraphy in breast cancer. Own experience
Afanasyeva N.G., Vazhenin A.V., Trofimchuk L.Y., Chvanova K.V.
Treatment of residual breast cancer
Ereschenko S.S., Semiglazov V.F., Krivorotko P.V., Dashyan G.A., Smirnova V.O., Komyakhov A.V., Gigolaeva L.P., Zhiltsova E.K.
GONADOTROPIN-RELEASING HORMONE AGONISTS-INDUCED OVARIAN SUPPRESSION IN EARLY BREAST CANCER
Semiglazova T.Y., Berlev I.V., Ulrikh E.A., Semiglazov V.V., Protasova A.E., Brish N.A., Korobeynikova E.A., Alekseeva Y.V., Filatova L.V., Semenova A.I., Latipova D.K., Teletaeva G.M., Tkachenko E.V., Klimenko V.V., Dashyan G.A., Protsenko S.A., Paltuev R.M., Urmancheeva A.F., Krivorotko P.V., Semiglazov V.F.
Kadsila (trastuzumab emtanzin, T-DM1): pervyy kon\"yugat antitela i khimiopreparata v lechenii HER2-polozhitel'nogo raka molochnoy zhelezy
Borisova E.I., Gutorov S.L., Lichinitser M.R.
Adjuvant hormonal therapy in perimenopausal women with ER-positive breast cancer
Semiglazov V.F., Semiglazov V.V.
Chemotherapy of anthracy-clineand taxan-resistant breast cancer
Kovalenko E.I., Satirova E.F., Artamonova E.V., Manzyuk L.V.
XELODA IN BREAST CANCER: THE EXPERIENCE OF LONG-TERM USE
Vladimirova L.Y., Popova I.L., Vladimirova L.Y., Popova I.L.
TARGET THERAPY HER2-POSITIVE BREAST CANCER WITH BRAIN METASTASES: NEW PROSPECTS FOR TREATMENT
Yu Semiglazova T., Filatova L.V., Kh Latipova D., Gershanovich M.L., Semiglazova T.Y., Filatova L.V., Khamidovna L.D., Gershanovich M.L.
Adjuvant and neoadjuvant therapy for (based on the materials of the 16th St. Gallen International Breast Cancer Conference)
Semiglazov V.F., Semiglazov V.V.
New possibilities of the treatment of breast cancer: microtubule inhibitors
Semiglazov V.F., Dashyan G.A., Krivorotko P.V., Paltuev R.M., Donskikh R.V., Semiglazova T.Y., Zernov K.Y., Gigolaeva L.P., Apollonova V.S.
FIRST-LINE ENDOCRINE THERAPY OF HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE METASTATIC BREAST CANCER. TIME OF CHANGE AFTER A LONG-TERM CALM PERIOD
Zhukova L.G., Manikhas A.G.
NOVYE VOZMOZhNOSTI TERAPII BOL'NYKh METASTATIChESKIM RAKOM MOLOChNOY ZhELEZY, POLUChAVShIKh RANEE ANTRATsIKLINI TAKSAN-SODERZhAShchUYu KhIMIOTERAPIYu: OBZOR LITERATURY I KLINIChESKIY SLUChAY
Zhukova L.G.
Adjuvant therapy with trastuzumab for early-stage breast cancer: 12 or 24 months (based on ESMO data, Vienna, october, 2012)
Zhukova L.G., Lichinitser M.R.
EVALUATION OF THE EFFECTIVENESS OF CHEMOTHERAPY OF BREAST CANCER WITH LUNG METASTASES
Andreyashkina I.I., Plokhov V.N., Andreyashkina I.I., Plokhov V.N.
RAK MOLOChNOY ZhELEZY U MUZhChIN
Semiglazov V.F., Semiglazov V.V., Dashyan G.A., Paltuev R.M., Migmanova N.S., Shchedrin D.E., Grechukhina I.A., Bessonov A.A., Pen'kov K.D., Merabishvili V.M.
LEChENIE OPERABEL'NYKh I OTNOSITEL'NO OPERABEL'NYKh FORM RAKA MOLOChNOY ZhELEZY
Semiglazov V.F., Dashyan G.A., Semiglazov V.V., Donskikh R.V., Paltuev R.M.
Will our clinical practice change with the availability of new diagnostic methods, drug therapy and assessment of its effectiveness? Clinical case: hormone receptor-positive, HER2-negative metastatic breast cancer
Konstantinova M.M., Kuzina L.I.
Olaparib -modern approach to the treatment of BRCA-associated HER2-negative metastatic breast cancer. Clinical experience
Lubennikova E.V., Zhukova L.G., Gordeeva O.O., Drobot N.T., Kuznetsov A.V., Ganshina I.P.
Search for new prognostic and predictive markers of sensitivity to endocrine therapy, chemotherapy and immunotherapy of breast cancer
Semiglazov V.F., Pesotsky R.S., Tseluiko A.I., Dzhelyalova M.A., Apollonova V.S., Semiglazov V.V.
New results of combination endocrinotherapy with ribocyclib
Kolyadina I.V.
Oral chemotherapy with vinorelbine for advanced breast cancer: its role in clinical practice
Sakaeva D.D., Nasretdinov A.F.
ANALYSIS OF INFLUENCE ON THE BUDGET OF THE RUSSIAN FEDERATION OF THE USE OF ORAL VINORELBINE FOR THE TREATMENT OF METASTATIC BREAST CANCER
Shabalkin P.I.
PLACE OF LAPATINIB IN THE THERAPY OF HER2-POSITIVE BREAST CANCER
Zhukova L.G., Ganshina I.P., Zaitsev V.G., Stepanchenko M.V.
KOMPLEKSNAYa TERAPIYa HER2-POZITIVNOGO RAKA MOLOChNOY ZhELEZY
Semiglazov V.F., Semiglazov V.V., Nikolaev K.S., Dashyan G.A., Paltuev R.M.
NOVYE PERSPEKTIVNYE PREPARATY DLYa LEChENIYa HER2-POZITIVNOGO RAKA MOLOChNOY ZhELEZY
Gorbunova V.A.
Znachenie molekulyarnykh markerov pri vybore neoad\"yuvantnoy khimioterapii mestno-rasprostranennogo raka molochnoy zhelezy
Semiglazova T.Y., Semiglazov V.V., Filatova L.V., Krivorot'ko P.V., Klimenko V.V., Ivanov V.G., Novikov S.M., Gershanovich M.L., Imyanitov E.N., Semiglazov V.F.
NANOTEKhNOLOGII V DIAGNOSTIKE I LEChENII ZLOKAChESTVENNYKh OPUKhOLEY
Semiglazov V.F., Paltuev R.M., Semiglazov V.V., Dashyan G.A., Bessonov A.A., Pen'kov K.D., Vasil'ev A.G.
NEOAD\"YuVANTNAYa ENDOKRINOTERAPIYa RAKA MOLOChNOY ZhELEZY
Semiglazov V.F., Semiglazov V.V., Ivanov V.G.
EXPERIENCE OF PERSONALIZED APPOINTMENT OF NEOADJUVANT CHEMOTHERAPY FOR PATIENT WITH BREAST CANCER: A PROSPECTIVE STUDY
Slonimskaya E.M., Kazantseva P.V., Litviakov N.V., Tsyganov M.M., Ibragimova M.K., Doroshenko A.V., Vernadsky R.U., Vostrikova M.A., Lushnikova N.A.
NEOADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCER
Semiglazov V.F., Semiglazov V.V., Dashyan G.A., Krivorotko P.V., Nikolaev K.S., Semiglazova T.Y., Komyakhov A.V., Bessonov A.A., Donskikh R.V., Paltuev R.M., Zernov K.Y.
LAPATINIB PRI RAKE MOLOChNOY ZhELEZY
Fray I.V., Perevodchikova N.I.
METODOLOGIChESKIE ASPEKTY MORFOLOGIChESKOY DIAGNOSTIKI I OTsENKI LEChEBNOGO PATOMORFOZA TROYNOGO NEGATIVNOGO RAKA MOLOChNOY ZhELEZY
Andreeva Y.Y., Zavalishina L.E., Danilova N.V., Ilatovskaya M.E., Frank G.A.
ROL' IMMUNOKON\"YuGATOV V TARGETNOY TERAPII ZLOKAChESTVENNYKh OPUKhOLEY
Semiglazov V.F., Dashyan G.A., Semiglazova T.Y., Paltuev R.M., Zernov K.Y., Pen'kov K.D., Grechukhina I.A., Semiglazov V.V.
Hormonal treatment of breast cancer: optimal sequence and issues of overcoming the resistance
Borisova E.I., Gutorov S.L., Vorontsov A.Y.
CLINICAL EXPERIENCE OF USE OF BEVACIZUMAB (AVASTIN) IN PATIENTS WITH METASTATIC BREAST CANCER WITH UNIDENTIFIED HER2/NEW AND ER PR-RECEPTOR STATUS
Konstantinova M.M., Shikina V.E., Makshantsev A.Y., Konstantinova M.M., Shikina V.Y., Makshantsev A.Y.
Bevatsizumab (Avastin) v lechenii bol'nykh rakom molochnoy zhelezy
Lud A.N., Gan'shina I.P.
ANTIANGIOGENNYE PREPARATY V LEChENII RAKA MOLOChNOY ZhELEZY
Semiglazov V.F., Dashyan G.A., Semiglazov V.V., Paltuev R.M., Krivorot'ko P.V., Kolar'kova V.V., Donskikh R.V., Shamina E.A., Tabagua T.T.
Endocrine resistance in breast cancer treatment
Dzhelyalova M.A., Semiglazov V.F.
A clinical case of using ribociclib with an aromatase inhibitor in metastatic hormone-receptor-positive HER2-negative breast cancer with a rare location of metastasis
Fateeva A.V., Zyuzyukina A.V., Zukov R.A.
Trastuzumab emtanzin in the treatment of HER2-positive metastatic breast cancer in patients with visceral crisis
Vladimirova L.Y., Popova I.L., Abramova N.A., Storozhakova A.E., Tikhanovskaya N.M., Novoselova K.A., Lyanova A.A., Ryadinskaya L.A., Yezhova M.O., Teplyakov M.A.
Ways to improve efficiency of endocrino-therapy of breast cancer: new targeted cells, new therapeutic opportunities
Semiglazov V.F., Semiglazov V.V., Nikolaev K.S., Dashyan G.A., Komyakhov A.V., Paltuev R.M., Appolonova V.S., Donskikh R.V., Tseluyko A.I., Semiglazova T.Y., Zhiltsova E.K., Krivorotko P.V.
Palbociclib - new possibilities of therapy of hormon-positive HER2-negative breast cancer
Zhukova L.G., Chichikov E.I., Gordeeva O.O., Filonenko D.A.
BONDRONAT - OPYT PRIMENENIYa U BOL'NYKh S KOSTNYMI METASTAZAMI RAKA MOLOChNOY ZhELEZY
Semenov N.N.
Effektivnost' i bezopasnost' preparata Ekstimiya®, novogo pegilirovannogo filgrastima: rezul'taty otkrytogo sravnitel'nogo klinicheskogo issledovaniya II fazy patsientov s rakom molochnoy zhelezy, poluchayushchikh mielosupressivnuyu khimioterapiyu
Sheveleva L.P., Khorinko A.V., Burdaeva O.N., Nechaeva M.N., Matrosova M.P., Kovalenko N.V., Ivanov R.A., Chernovskaya T.V., Salafet O.V.
A new approach to the overcoming resistance to hormone therapy of breast cancer
Semiglazova T.Y., Semiglazov V.V., Filatova L.V., Krivorot'ko P.V., Klimenko V.V., Gershanovich M.L., Semiglazov V.F.
Opyt primeneniya trastuzumaba v respublike Bashkortostan
Sakaeva D.D., Kunafina R.I., Popova E.V.
RESORBA IN THE TREATMENT OF BONE METASTASIS OF BREAST CANCER
Vladimirova L.Y., Abramova N.A., E Storozhakova A., Paly A.L., Vladimirova L.Y., Abramova N.A., Storozhakova A.E., Paliy A.L.
ADJUVANT ANTI-HER2 THERAPY FOR BREAST CANCER
Semiglazov V.F., Semiglazov V.V., Ivanov V.G., Bessonov A.A., Shchedrin D.Y., Zhiltsova Y.K., Dashyan G.A., Paltuev R.M., Semiglazova T.Y., Penkov K.D., Vasilyev A.G., Semiglazov V.F., Semiglazov V.V., Ivanov V.G., Bessonov A.A., Shchedrin D.E., Zhil'tsova E.K., Dashyan G.A., Paltuev R.M., Semiglazova T.Y., Pen'kov K.D., Vasil'ev A.G.
RASPROSTRANENNOST', OSOBENNOSTI TEChENIYa I FARMAKOTERAPII OSTEOPOROZA U ONKOLOGIChESKIKh BOL'NYKh
Vertkin A.L., Naumov A.V., V Kozlova O., Maksimenko E.V., Khimich Y.A.
RAK MOLOChNOY ZhELEZY I BEREMENNOST'
Dashyan G.A., Semiglazov V.F., Semiglazov V.V., Migmanova N.S., Krivorot'ko P.V., Tabagua T.T., Vasil'ev A.G.
Treatment of HER2-positive early (minimal) breast cancer
Pesotsky R.S., Semiglazov V.F., Tseluyko A.I., Sokolova M.D., Mortada V.V., Tabagua T.T., Krivorotko P.V.
Ways to improve endocrine therapy in postmenopausal women with ER+/ HER2- breast cancer
Dzhelyalova M.A., Semiglazov V.F.
Predictive and prognostic significance of stemness gene amplifications in the breast tumor in patients who received neoadjuvant chemotherapy
Kazantseva P.V., Slonimskaya E.M., Tsyganov M.M., Ibragimova M.K., Doroshenko A.V., Tarabanovskaya N.A., Litviakov N.V.
De-escalation and escalation of treatment of patients with HER2-positive breast cancer
Semiglazov V.F., Semiglazov V.V., Nikolaev K.S., Komyakhov A.V., Semiglazova T.Y., Paltoev R.M., Donskikh R.V., Tseluyko A.I., Artemyeva A.S., Bashlyk V.O., Miryusupova G.F., Dashyan G.A.
15-letniy opyt ispol'zovaniya Gertseptina pri HER2-pozitivnom rake molochnoy zhelezy
Mukhametshina G.Z., Lichinitser M.R., Lubennikova E.V.
ChETYRE ASPEKTA AD\"YuVANTNOY TARGETNOY TERAPII HER2-POZITIVNOGO RAKA MOLOChNOY ZhELEZY
Semiglazov V.F., Semiglazov V.V.
Effektivnost' i bezopasnost' ezhenedel'nogo vvedeniya paklitaksela bol'nym metastaticheskim rakom molochnoy zhelezy: rezul'taty prospektivnogo mnogotsentrovogo klinicheskogo issledovaniya
Stroyakovskiy D.L., Makhson A.N., Bolotina L.V., Gorbunova V.A., Koroleva L.A., Bagrova S.G., Borisova T.A., Kornietskaya A.L., Ivanov R.A., Nikitin K.D.
TARGETED THERAPY AFTER PROGRESSION OF HER-2-POSITIVE BREAST CANCER
Tat'yana Y.S., Semiglazov V.V., Larisa V.F., Chubenko V.A., Nikita V.B., Fedor V.M., Latipova D.K., Mikhail L.G., Semiglazova T.Y., Semiglazov V.V., Filatova L.V., Chubenko V.A., Brejnev N.V., Moiseenko F.V., Latipova D., Gershanovich M.L.
DRUG ZOMETA IN ADDITION TO THE CHEMOTHERAPY SIGNIFICANTLY INCREASES OVERALL SURVIVAL IN PREVIOUSLY UNTREATED PATIENTS WITH MULTIPLE MYELOMA
Zhukov N.V., Zhukov N.V.
NEOADJUVANT THERAPY OF THE BREAST CANCER WITH HIGH EXPRESSION OF HER-2
Semiglazov V.F., Manikhas A.G., Bozhok A.A., Dashjan G.A., Vasilev A.G., Petrovsky S.G., Matsko D.Y., Semiglazov V.V., Paltuev R.M., Ivanov V.G., Zernov K.Y., Donskikh R.V., Bessonov A.A., Shamina Y.A., Semiglazov V.F., Manikhas A.G., Bozhok A.A., Vasil'ev A.G., Petrovskiy S.G., Matsko D.E., Semiglazov V.V., Dashyan G.A., Paltuev R.M., Ivanov V.G., Zernov K.Y., Donskikh R.V., Bessonov A.A., Shamina E.A.
KOSTNYE METASTAZY PRI RAKE MOLOChNOY ZhELEZY: Skol'ko stoit terapiya bisfosfonatami?
Yagudina R.I., Krysanov I.S.
Clinical significance of genetic polymorphism of tamoxifen metabolic enzymes and transporters in breast cancer: results of a population-based cohort study
Golubenko E.O., Savelyeva M.I., Sozaeva Z.A., Poddubnaya I.V., Korennaya V.V.
Predictive and prognostic role of tumor-infiltrating lymphocytes (TILs) in early triple-negative breast cancer
Abdulaeva S.R., Semiglazova T.Y., Artemyeva A.S., Kudaibergenova A.G., Sharashenidze S.M., Tseluyko A.I., Paltuev R.M., Semiglazov V.V., Krivorotko P.V., Semiglazov V.F.
Dual HER2 blockade with pertuzumab+trastuzumab on the eve of a new era in the treatment of HER2-positive breast cancer
Zhukova L.G., Artamonova E.V., Ganshina I.P., Kolyadina I.V., Vorontsova K.A., Sekhina O.V., Grechukhina K.S.
CYCLIN-DEPENDENT KINASE INHIBITORS - NEW THERAPEUTIC OPTION FOR PATIENTS WITH HORMONE-DEPENDENT HER2-NEGATIVE BREAST CANCER: CLINICAL EXPERIENCE
Sakaev D.D., Iskhakova A.I., Kunafina R.I.
TAXANES IN THE TREATMENT OF BREAST CANCER
Semiglazov V.F., Dashyan G.A., Semiglazov V.V., Paltuev R.M., Semiglazova T.Y., Donskikh R.V., Nikolaev K.S., Komyakhov A.V., Zernov K.Y., Krivorotko P.V.
EFFECT OF SPECIAL TREATMENT ON THE DEVELOPMENT OF OSTEOPOROSIS IN PATIENTS WITH BREAST CANCER IN PREMENOPAUSAL PERIOD
Tretyakova N.Y.
Redkiy sluchay otdalennogo metastazirovaniya raka molochnoy zhelezy v okoloushnuyu slyunnuyu zhelezu
Krasikova Y.P., Klochikhin M.A., Klochikhin A.L.
Novyy sposob radikal'noy rezektsii pri rake molochnoy zhelezy nizhnikh lokalizatsiy
Parandey I.N., Orlov O.A.
Eribulin v lechenii metastaticheskogo raka molochnoy zhelezy s troynym negativnym fenotipom
Zhukova L.G., Okruzhnova M.A., Chasovnikova E.O.
ROL' LIPOSAKTsII V LEChENII POSTMASTEKTOMIChESKOY LIMFEDEMY
Zabelin M.V., Sidorov D.B., Safonov A.S.
Effektivnost' nizkikh doz gemtsitabina v kombinatsii s tsisplatinom v lechenii disseminirovannogo raka molochnoy zhelezy s progressirovaniem posle primeneniya antratsiklinov, taksanov i kapetsitabina
Semiglazova T.Y., Gershanovich M.L., Latipova D.K., Filatova L.V., Chubenko V.A., Semiglazov V.V., Matsko D.E., Klimenko V.V.
TARGETED THERAPY OF BREAST CANCER (NEW DIRECTIONS)
Semiglazov V.F., Dashyan G.A., Semiglazov V.V., Paltuev R.M., Manikhas A.G., Bessonov A.A., Ermachenkova A.M., Shchedrin D.E., Tabagua T.T., Grechukhina I.A., Krivorot'ko P.V., Donskikh R.V., Semiglazova T.Y., Kolar'kova V.V., Semiglazo V.F., Dashyan G.A., Semiglazov V.V., Paltuev R.M., Manikhas A.G., Bessonov A.A., Yermachenkova A.M., Schedrin D.Y., Tabagua T.T., Grechukhina I.A., Krivorotko P.V., Donskih R.V., Semiglazova T.Y., Kolarkova V.V.
Ixabepilone in the treatment of breast cancer
Semiglazov V.F., Krivorotko P.V., Semiglazova T.Y., Komyakhov A.V., Tabagua T.T., Kazantseva M.D., Zhiltsova E.K., Ulrikh D.G., Chervyak M.V., Tergoeva A.P., Klimenko V.V., Semiglazov V.V.
Clinical immunology of breast cancer
Tseluiko A.I., Semiglazov V.F., Kudaibergenova A.G., Artemyeva A.S., Paltuev R.M., Donskikh R.V., Pesotsky R.S., Krivorotko P.V.
Ixempra - new possibilities of cytostatic therapy of breast cancer
Lubennikova E.V., Zhukova L.G., Arutyunyan E.A.
RESOLUTION SUMMARIZING THE RESULTS OF THE EXPERT COUNCIL "MODERN APPROACHES TO THE TREATMENT OF HER2-NEGATIVE METASTATIC BREAST CANCER. PROSPECTS FOR THE USE OF ERIBULIN AS A PART OF COMBINATION THERAPY FOR BREAST CANCER"
Artamonova E.V., Bolotina L.V., Gligorov Z., Zhukov N.V., Zhukova L.G., Imyanitov E.N., Karabina E.V., Kovalenko E.I., Lichinitser M.R., Manzyuk L.V., Semiglazov V.F., Semiglazova T.Y., Stroyakovsky D.L.
Rak molochnoy zhelezy i beremennost'
Dashyan G.A., Semiglazov V.F., Topuzov E.E., Ivanov V.G., Vorotnikov V.V., Lalak I.A., Bryantseva Z.V., Usungvan M.V., Tseluyko A.I.
PRIMENENIE BISFOSFONATOV DLYa PROFILAKTIKI RAZVITIYa KOSTNYKh METASTAZOV U BOL'NYKh RAKOM MOLOChNOY ZhELEZY
Semenov N.N.
INDIVIDUALIZATION OF ADJUVANT THERAPY OF BREAST CANCER
Semiglazov V.F., Semiglazov V.V., Paltuev R.M., Dashyan G.A., Manikhas A.G., Pen'kov K.D., Semiglazova T.Y., Tabagua T.T., Vasil'ev A.G., Kolar'kova V.V., Krivorot'ko P.V., Nikitina I.V., Semiglazov V.F., Semiglazov V.V., Paltuyev R.M., Dashyan G.A., Manihas A.G., Penkov K.D., Semiglazova T.Y., Tabagua T.T., Vasilyev A.G., Korolkova V.V., Krivorotko P.V., Nikitina I.V.
1 - 100 of 100 Items

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default only articles containing all terms in the query are returned (i.e., AND is implied)
  • Combine multiple words with OR to find articles containing either term; e.g., education OR research
  • Use parentheses to create more complex queries; e.g., archive ((journal OR conference) NOT theses)
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing"
  • Exclude a word by prefixing it with - or NOT; e.g. online -politics or online NOT politics
  • Use * in a term as a wildcard to match any sequence of characters; e.g., soci* morality would match documents containing "sociological" or "societal"

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies